The earnings result
Regeneron Pharmaceuticals reported earnings on 2026-01-30 for the fiscal quarter ending Dec/2025. Reported EPS of $9.9 compared with a consensus estimate of $8.28, a beat on the source's earnings measure.
An EPS comparison describes one part of the release. Revenue, segment performance, cash conversion, guidance and the conference-call discussion require the original company disclosures; the result alone does not establish why the stock moved.
The market response
Price baseline: pre-report close. The baseline follows the reported announcement session.
The first measured session returned -1.07% from the stated baseline. The five-session return was +2.29%, and the 20-session return was +4.30%. SPY returned -1.16% across the corresponding window. Relative volume was 1.51 times the preceding 20-session average.
This edition is a source-based earnings-result and market-response analysis. A full financial-statement and conference-call dossier is not yet attached.